Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iressa Committee Will Not Vote On Market Withdrawal; FDA To Review Data

Executive Summary

FDA's Oncologic Drugs Advisory Committee will not vote on whether the lung cancer therapy Iressa should be removed from the market during its March 4 meeting, AstraZeneca said

You may also be interested in...



Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July

FDA will bring AstraZeneca's oncologic Iressa back before the Oncologic Drugs Advisory Committee in June or July, Division of Oncologic Drug Products Director Richard Pazdur indicated

Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July

FDA will bring AstraZeneca's oncologic Iressa back before the Oncologic Drugs Advisory Committee in June or July, Division of Oncologic Drug Products Director Richard Pazdur indicated

AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva

AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4

Related Content

Topics

UsernamePublicRestriction

Register

PS045337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel